Boehringer Ingelheim Enters Global Phase 3 Clinical Trial for FSGS Therapy Apecotrep (BI 764198)
Mechanism of Action Targeting TRPC6 and Overview of Phase 3 Clinical Trial for Apecotrep
Boehringer Ingelheim, a global pharmaceutical company based in Germany, has launched a global Phase 3 trial (NCT07220083) of the oral TRPC6 (Transient Receptor Potential Cation Channel Subfamily C Member 6) inhibitor apecotrep (BI 764198) for the treatment of focal segmental glomerulosclerosis (FSGS). The study will enroll approximately 286 adult and adolescent patients aged 12 years and older to evaluate the long‑term efficacy and safety of apecotrep versus placebo over up to 104 weeks. By selectively inhibiting podocyte injury, apecotrep protects the renal filtration barrier and targets the underlying pathogenic mechanism of the disease. The trial is designed to overcome the serious adverse effects associated with existing immunosuppressive therapies and to improve patient convenience.
Phase 2 Results Demonstrating Reduction in Proteinuria
In the global Phase 2 study, apecotrep demonstrated a robust reduction in proteinuria, establishing its therapeutic potential. The findings were presented at the 2025 American Society of Nephrology (ASN) meeting and subsequently published in The Lancet in February 2026. At the 12‑week time point, the 20 mg apecotrep arm achieved a statistically significant 40 % reduction in proteinuria compared with placebo. This compelling clinical data provided a critical springboard for Boehringer Ingelheim to initiate a large‑scale Phase 3 program. The reduction in proteinuria—a key disease endpoint—enhances the likelihood of regulatory approval.
Launch of Filspari and Intensifying Competitive Landscape
The global FSGS therapeutic market is estimated to expand from roughly $14 billion in 2025 to $16 billion in 2026, representing a sizable blue‑ocean opportunity. In April 2026, Travere Therapeutics secured the first FDA approval for Filspari (sparsentan), positioning it as an early market entrant. Concurrently, Vertex is accelerating Phase 3 development of inaxaplin (VX‑147), which targets APOL1‑mediated disease. To achieve a competitive advantage, apecotrep must demonstrate superior renal protection and long‑term dosing convenience relative to Filspari in the ongoing Phase 3 trial.
Boehringer Ingelheim’s Renal Disease Portfolio Strategy
Boehringer Ingelheim, a privately held pharmaceutical company, has developed apecotrep through internal R&D without external licensing. Consequently, there are no partnership or milestone obligations, allowing the company to maximize margins upon successful commercialization. Leveraging its existing cardiovascular‑renal‑metabolic (CRM) portfolio, which includes the diabetes therapy Jardiance, Boehringer Ingelheim aims to extend its reach into rare‑disease indications with apecotrep. A successful Phase 3 outcome would cement apecotrep’s position as a next‑generation oral targeted therapy in the FSGS market and generate a new growth engine for the company.
The entry of apecotrep (BI 764198) into global Phase 3 trials marks the commencement of next‑generation, precision‑medicine competition in the roughly $14‑$16 billion worldwide FSGS market, following the April 2026 FDA approval of the first FSGS therapy, Filspari. From an investor perspective, Boehringer Ingelheim—already a dominant player in the CRM market with Jardiance—can leverage its internally developed TRPC6 asset to maximize the high‑margin value of a rare‑kidney‑disease pipeline and drive long‑term growth. For drug developers and researchers, the 40 % proteinuria reduction observed in Phase 2 provides a pivotal scientific milestone to validate whether TRPC6‑mediated protection of podocytes translates into sustained renal function preservation in patients. In the medium to long term, the emergence of APOL1‑targeted agents such as Vertex’s inaxaplin (VX‑147) together with biomarker‑driven precision‑medicine approaches is expected to diversify the standard of care for rare chronic kidney diseases.
Source: ClinicalTrials.gov (api_ct)